ATE435231T1 - Verfahren zur herstellung verzweigterribonukleoside aus 1,2- anhydroribofuranose-zwischenprodukten - Google Patents

Verfahren zur herstellung verzweigterribonukleoside aus 1,2- anhydroribofuranose-zwischenprodukten

Info

Publication number
ATE435231T1
ATE435231T1 AT04709000T AT04709000T ATE435231T1 AT E435231 T1 ATE435231 T1 AT E435231T1 AT 04709000 T AT04709000 T AT 04709000T AT 04709000 T AT04709000 T AT 04709000T AT E435231 T1 ATE435231 T1 AT E435231T1
Authority
AT
Austria
Prior art keywords
anhydroribofuranose
intermediate products
producing branched
branched ribonucleosides
ribonucleosides
Prior art date
Application number
AT04709000T
Other languages
English (en)
Inventor
Feng Xu
Matthew Bio
Cameron Cowden
Kimberly Savary
John Williams
Chunhua Yang
Marjorie Waters
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE435231T1 publication Critical patent/ATE435231T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AT04709000T 2003-02-12 2004-02-06 Verfahren zur herstellung verzweigterribonukleoside aus 1,2- anhydroribofuranose-zwischenprodukten ATE435231T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44693503P 2003-02-12 2003-02-12
PCT/US2004/003469 WO2004072090A1 (en) 2003-02-12 2004-02-06 Process for preparing branched ribonucleosides from 1, 2-anhydroribofuranose intermediates

Publications (1)

Publication Number Publication Date
ATE435231T1 true ATE435231T1 (de) 2009-07-15

Family

ID=32869576

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709000T ATE435231T1 (de) 2003-02-12 2004-02-06 Verfahren zur herstellung verzweigterribonukleoside aus 1,2- anhydroribofuranose-zwischenprodukten

Country Status (7)

Country Link
US (1) US7339054B2 (de)
EP (1) EP1594882B1 (de)
AR (1) AR043006A1 (de)
AT (1) ATE435231T1 (de)
DE (1) DE602004021774D1 (de)
TW (1) TWI320787B (de)
WO (1) WO2004072090A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (de) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Behandlung von Flaviviren und Pestiviren
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004009020A2 (en) 2002-07-24 2004-01-29 Merck & Co., Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
AR043006A1 (es) * 2003-02-12 2005-07-13 Merck & Co Inc Proceso para preparar ribonucleosidos ramificados
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
JP2012521359A (ja) * 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
EP2552203B1 (de) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
EP2906579B1 (de) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chlor-nukleosidanaloga für hcv-infektion
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EP2935304A1 (de) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluor-nukleoside zur behandlung von hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (de) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluor-nukleoside zur behandlung von hcv
US9447132B2 (en) 2013-04-12 2016-09-20 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
EP3773753A4 (de) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. Behandlung von hcv-infizierten patienten mit zirrhose
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US20220251088A1 (en) * 2020-12-10 2022-08-11 Prelude Therapeutics, Incorporated Processes for Making PRMT5 Inhibitors
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
US3480613A (en) * 1967-07-03 1969-11-25 Merck & Co Inc 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (de) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Behandlung von Flaviviren und Pestiviren
WO2002032920A2 (en) 2000-10-18 2002-04-25 Pharmasset Limited Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
SK286630B6 (sk) * 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
AR043006A1 (es) * 2003-02-12 2005-07-13 Merck & Co Inc Proceso para preparar ribonucleosidos ramificados
EP1804812A4 (de) * 2004-10-21 2009-09-02 Merck & Co Inc Fluorierte pyrrolo[2,3-d]pyrimidin-nukleoside zur behandlung rna-abhängiger rna-virusinfektionen

Also Published As

Publication number Publication date
EP1594882B1 (de) 2009-07-01
TW200508244A (en) 2005-03-01
WO2004072090A1 (en) 2004-08-26
DE602004021774D1 (de) 2009-08-13
US7339054B2 (en) 2008-03-04
US20070037771A1 (en) 2007-02-15
AR043006A1 (es) 2005-07-13
TWI320787B (en) 2010-02-21
EP1594882A1 (de) 2005-11-16

Similar Documents

Publication Publication Date Title
ATE435231T1 (de) Verfahren zur herstellung verzweigterribonukleoside aus 1,2- anhydroribofuranose-zwischenprodukten
ATE340819T1 (de) Verfahren zur herstellung von polyamiden
ATE414077T1 (de) Verfahren zur herstellung von 1-ä(benzimidazol-1- yl)chinolin-8-ylüpiperidin-4-ylaminderivaten
DE602004003964D1 (de) Verfahren zur herstellung verzweigter kohlenwasserstoffe
DE60211535D1 (de) Verfahren zur herstellung von 2,5-diformylfuran aus kohlenhydraten
DE602005026478D1 (de) Verfahren zur Herstellung von dünnwandigen Isogittergehäusen
ATE515500T1 (de) Verfahren zur herstellung von telmisartan
ATE453648T1 (de) Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
DE602004011531D1 (de) Verfahren zur herstellung von dünnen blechen aus hochfesten titanlegierungen
DE50308650D1 (de) Verfahren zur herstellung von cellulosecarbamatformkörpern
ATE376997T1 (de) Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten
ATE506351T1 (de) Verfahren zur herstellung von 10,11-dihydro-10- oxo-5h-dibenzoäb,füazepin-5-carboxamid
ATE553103T1 (de) Verfahren zur herstellung von (s)-pantoprazol
DE602004004677D1 (de) Verfahren zur herstellung substituierter 5-amino-pyrazolo-ä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine
ATE430140T1 (de) Verfahren zur herstellung von ä1,4,5ü- oxadiazepinderivaten
DE502004006260D1 (de) Verfahren zur herstellung von 1-octen aus crack-c4
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
ATE374757T1 (de) Verfahren zur herstellung von (1,4,5)- oxadiazepinderivaten
DE60134415D1 (de) Verfahren zur herstellung von wäscheweichmacherzusammensetzungen
DE502005007702D1 (de) Verfahren zur herstellung von terrylen-3,4:11,12-t
ATE402138T1 (de) Verfahren zur herstellung von 2- aminoindanderivaten
DE60314113D1 (de) Verfahren zur herstellung von phenylorganosiliciumzwischenprodukten
DE602004004777D1 (de) Kontinuierliches verfahren für die herstellung von polyamiden
DE602004030177D1 (de) Verfahren zur Herstellung von Natriumborhydrid aus Natriumaluminiumhydrid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties